TWA
FATE icon

TCI Wealth Advisors’s Fate Therapeutics FATE Stock Holding History

TCI Wealth Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-594
Closed -$5.99K – 2556
2022
Q4 		$5.99K Buy
594
+225
+61% +$4.23K ﹤0.01% 1403
2022
Q3 		$8K Buy
369
+87
+31% +$2.51K ﹤0.01% 1146
2022
Q2 		$7K Buy
282
+132
+88% +$3.64K ﹤0.01% 1235
2022
Q1 		$6K Sell
150
-255
-63% -$9.87K ﹤0.01% 1411
2021
Q4 		$24K Buy
405
+61
+18% +$3.46K ﹤0.01% 627
2021
Q3 		$20K Buy
344
+86
+33% +$6.75K ﹤0.01% 692
2021
Q2 		$22K Sell
258
-315
-55% -$25.4K ﹤0.01% 586
2021
Q1 		$47K Buy
573
+73
+15% +$7K 0.02% 363
2020
Q4 		$45K Sell
500
-300
-38% -$18.6K 0.02% 351
2020
Q3 		$32K Sell
800
-25
-3% -$873 0.01% 374
2020
Q2 		$28K Hold
825
– – 0.01% 390
2020
Q1 		$18K Sell
825
-100
-11% -$2.53K 0.01% 462
2019
Q4 		$18K Sell
925
-400
-30% -$6.35K 0.01% 568
2019
Q3 		$21K Sell
1,325
-100
-7% -$1.92K 0.01% 482
2019
Q2 		$29K Hold
1,425
– – 0.01% 404
2019
Q1 		$25K Sell
1,425
-300
-17% -$4.74K 0.01% 450
2018
Q4 		$22K Buy
1,725
+100
+6% +$1.39K 0.01% 455
2018
Q3 		$26K Sell
1,625
-100
-6% -$1.18K 0.01% 446
2018
Q2 		$20K Buy
1,725
+100
+6% +$1.1K 0.01% 481
2018
Q1 		$16K Buy
1,625
+100
+7% +$958 0.01% 526
2017
Q4 		$9K Sell
1,525
-75
-5% -$335 ﹤0.01% 654
2017
Q3 		$6K Buy
1,600
+800
+100% +$2.72K ﹤0.01% 695
2017
Q2 		$3K Buy
800
+300
+60% +$1.15K ﹤0.01% 869
2017
Q1 		$2K Hold
500
– – ﹤0.01% 929
2016
Q4 		$1K Buy
+500
New +$1.34K ﹤0.01% 1153

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

TCI Wealth Advisors's FATE Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 594 shares — an estimated $5.99K sold.

TCI Wealth Advisors first reported a position in FATE in Q4 2016 and held it in 25 quarters. The position peaked at $47K in Q1 2021. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • TCI Wealth Advisors reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 594 Fate Therapeutics shares in Q1 2023, an estimated $5.99K.
  • TCI Wealth Advisors first reported a position in Fate Therapeutics in Q4 2016 and held it in 25 quarters.
  • TCI Wealth Advisors's Fate Therapeutics position peaked at $47K in Q1 2021.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.